Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ofatumumab vs Continued Therapy in Relapsing-remitting Multiple Sclerosis (SOSTOS)
NCT05090371Phase 4Active, not recruiting
- Sponsor
- Novartis
- Start
- Mar 2022
- Primary completion
- Apr 2027
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 4, randomised, open-label trial of ofatumumab in relapsing-remitting multiple sclerosis (RRMS) (2 arms), sponsored by Novartis. Primary endpoint: No Evidence of Disease Activity-3. Started Mar 2022; status: active, not recruiting.
02
Drugs
ofatumumab
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT05090371.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05090371.